Authors: Brandes, A.A.; Basso, U.; Pasetto, L.M.; Ermani, M.

Source: Current Pharmaceutical Design, Volume 7, Number 16, 1 November 2001 , pp. 1553-1580(28)

Publisher: Bentham Science Publishers

Abstract:

Background: The incidence of brain and other central nervous system malignant neoplasias is 6.5 cases per 100,000 inhabitants-years, and appears to increase with increasing age (1.2 percent per year), with the greatest rate of increase in the population over age 70 years. Material and methods: Chemotherapy remains part of the treatment that includes surgery and radiation therapy for the management of malignant gliomas. This article reviews the new drugs that have been introduced in the treatment of these patients in the latest years, their specific cellular targets, the objective response, the TTP and the MST. Results: The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years, and from clinical trials of CPT11. Conclusions: New approaches to chemotherapy treatment are necessary. Enrollment of patients into rigorous, well conducted, clinical trials, both at tumor diagnosis and recurrence, will generate new information regarding investigational therapies, and may offer improved therapies for patients with malignant gliomas.

Keywords: Brain Tumor Therapy; Chemotherapy; temozolomide; multidrug resistance gene (MDR); glutathione-S-transferase; procarbazine; poly (ADP)-ribose; polymerase (PARP); human astrocytoma (AA); glioblastoma (GBM)

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397221

Publication date: 2001-11-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Brandes, A.A. ;  Basso, U. ;  Pasetto, L.M. ;  Ermani, M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers